+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Mesalazine"

Irritable bowel syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Irritable bowel syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
From
Research Report on China's Mesalazine Market, 2021-2025 - Product Thumbnail Image

Research Report on China's Mesalazine Market, 2021-2025

  • Report
  • September 2021
  • 40 Pages
  • China
From
From
Mesalamine (CAS 89-57-6) Global Market Research Report 2024 - Product Thumbnail Image

Mesalamine (CAS 89-57-6) Global Market Research Report 2024

  • Report
  • April 2024
  • 50 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Mesalazine is a drug used to treat gastrointestinal diseases such as ulcerative colitis and Crohn's disease. It is a type of aminosalicylate, which works by reducing inflammation in the digestive tract. It is available in both oral and rectal forms, and is often used in combination with other medications. Common side effects include nausea, headache, and abdominal pain. Mesalazine is a widely used drug in the gastrointestinal market, and is often prescribed as a first-line treatment for inflammatory bowel diseases. It is generally well-tolerated and has a low risk of serious side effects. It is also used to treat other conditions such as pouchitis and microscopic colitis. The mesalazine market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, AstraZeneca, and Novartis. Show Less Read more